Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2020-06-17
- Target Recruit Count
- 39
- Registration Number
- NCT02726503
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya-city, Aichi-prefecture, Japan
🇯🇵Kuma Hospital, Kobe-city, Hyogo-prefecture, Japan
🇯🇵IUHW Ichikawa Hospital, Ichikawa-city, Chiba-prefecture, Japan
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 482
- Registration Number
- NCT02720068
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
- Conditions
- Interventions
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 241
- Registration Number
- NCT02702388
- Locations
- 🇮🇹
Facility #6, Milano, Italy
🇰🇷Facility#1, Busan, Korea, Republic of
🇦🇺Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02686164
- Locations
- 🇺🇸
Facility # 1, San Antonio, Texas, United States
Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Target Recruit Count
- 111
- Registration Number
- NCT02678780
- Locations
- 🇦🇹
Universitätsklinik für Innere Medizin, Graz, Austria
🇦🇹Medizinische Universität Wien, Wien, Austria
🇪🇸Hospital Central de Asturias, Oviedo, Asturias, Spain
Eribulin and Lenvatinib in Advanced Solid Tumors
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Virginia G. Kaklamani
- Target Recruit Count
- 29
- Registration Number
- NCT02640508
- Locations
- 🇺🇸
Cancer Therapy and Research Center University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT02592356
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT02579616
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02578316
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 357
- Registration Number
- NCT02501096
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Mass General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.